Currently Viewing:
Newsroom
Currently Reading
Breakthrough for Daratumumab for Use as Second Line With Standard of Care in Multiple Myeloma
July 26, 2016 – Surabhi Dangi-Garimella, PhD
California Experiment Will Let Pathologists Report Cancer Diagnoses in Real Time
July 25, 2016 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care July 23, 2016
July 23, 2016
Should There Be a Worldwide Standard List of Essential Diagnostic Tests?
July 22, 2016 – Jackie Syrop
First Cancer Trial Using CRISPR-Edited Cells to Begin Soon in China
July 22, 2016 – Surabhi Dangi-Garimella, PhD
New Multiple Myeloma Drug Interferes With Routine Testing Prior to a Transfusion
July 22, 2016 – Surabhi Dangi-Garimella, PhD
ctDNA Could Predict Relapse in Ovarian Cancer Earlier
July 21, 2016 – Surabhi Dangi-Garimella, PhD
St. Jude Study Stresses Importance of Survivor- and Parent-Reported Behavioral Symptoms
July 20, 2016 – Surabhi Dangi-Garimella, PhD
FDA Rejects Novartis' Biosimilar Application for Pegfilgrastim, Seeks Additional Information
July 20, 2016 – Surabhi Dangi-Garimella, PhD

Breakthrough for Daratumumab for Use as Second Line With Standard of Care in Multiple Myeloma

Surabhi Dangi-Garimella, PhD
The monoclonal antibody daratumumab (Darzalex) has been granted breakthrough designation, the second for this drug, for use in combination with either lenalidomide and dexamethasone or bortezomib and dexamethasone, for patients with multiple myeloma who have received at least 1 prior therapy.
The monoclonal antibody daratumumab (Darzalex) has been granted breakthrough designation, the second for this drug, for use in combination with either lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone, for patients with multiple myeloma who have received at least 1 prior therapy.

The drug was first approved in November 2015 in heavily pretreated patients diagnosed with multiple myeloma. The new breakthrough status was based on the results of 2 pivotal phase 3 studies:

  • MMY3004 (CASTOR) trial, which evaluated daratumumab in combination with the immunomodulatory agent dexamethasone and the proteasomal inhibitor bortezomib, compared with bortezomib and dexamethasone alone, in patients who had received just a single prior line of therapy.
  • MMY3003 (POLLUX) trial, which evaluated daratumumab in combination with dexamethasone and the immunomodulatory agent lenalidomide, compared with dexamethasone and lenalidomide alone, in patients who had received just a single prior line of therapy.
Both trials found that including daratumumab reduced the risk of disease progression as well as death in patients with multiple myeloma.

“This is the second time daratumumab has earned the distinction of a Breakthrough Therapy Designation. We are pleased that the FDA continues to recognize the potential of daratumumab to help patients with multiple myeloma. We continue to work with our strategic partner Janssen and the regulatory authorities to advance daratumumab to bring this treatment to more patients suffering from multiple myeloma as quickly as possible,” said Jan van de Winkel, PhD, chief executive officer of Genmab, which is developing the drug in collaboration with Janssen Research and Development.    

Craig L. Tendler, MD, vice president, Late-Stage Development and Global Medical Affairs for Oncology, Hematology and Supportive Care, Janssen, said, “This is an important recognition of the transformative potential of daratumumab and its possible benefit as a backbone therapy in combination with two of the most widely used regimens for multiple myeloma.”

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up